Literature DB >> 10937949

Angiotensin-II type 1 receptor gene polymorphism and long-term survival in patients with idiopathic congestive heart failure.

B Andersson1, I Blange, C Sylvén.   

Abstract

BACKGROUND: It has been suggested that a genetic polymorphism in the angiotensin II type 1 receptor gene (ATRG) and the ACE gene DD genotype might have a synergistic influence on the risk of developing cardiovascular disease. AIMS: To study the possible interaction between polymorphisms in the ACE gene and the ATRG, regarding survival and left ventricular function.
METHODS: Polymorphism of the two genes was studied in a population-based cohort of 194 patients with idiopathic heart failure, recruited from the western part of Sweden 1985-1988. The patients were investigated by echocardiography. The survival status was checked during the 7-year follow-up period.
RESULTS: Although there was no statistically significant additive risk of the ATRG polymorphism, patients carrying the ACE gene DD genotype in combination with a C allele of the ATRG tended to have a poorer prognosis. DD +AA, OR 1.24 (95% CI 0.67-2.32, P = 0.49); DD +AC, OR 1.64 (95% CI 0.95-2.83, P = 0.08); DD + CC, OR 3.54 95% CI 0.78-16.1, P = 0.10); DD +AC/CC, OR 1.84 (95% CI 1.10-3.08, P = 0.02). Patients with the DD +AC/CC genotypes tended to have lower ejection fraction and increased left ventricular mass.
CONCLUSIONS: There was a trend toward a worse prognosis in patients with the combination of a C-allele in the ATRG and the ACE gene DD genotype, suggesting an interaction of these two genetic polymorphisms on disease severity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10937949     DOI: 10.1016/s1388-9842(99)00045-8

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  16 in total

1.  RAAS and adrenergic genes in heart failure: Function, predisposition and survival implications.

Authors:  Alberto J Alves; Nir Eynon; José Oliveira; Ehud Goldhammer
Journal:  World J Cardiol       Date:  2010-07-26

Review 2.  Targeting tissue angiotensin-converting enzyme for imaging cardiopulmonary fibrosis.

Authors:  Omer Aras; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2008-03       Impact factor: 2.931

Review 3.  The genomic architecture of sporadic heart failure.

Authors:  Gerald W Dorn
Journal:  Circ Res       Date:  2011-05-13       Impact factor: 17.367

4.  Angiotensin-converting enzyme genetic polymorphism.

Authors:  Somsri Wiwanitkit; Viroj Wiwanitkit
Journal:  Arq Bras Cardiol       Date:  2014-06       Impact factor: 2.000

Review 5.  Genetics of dilated cardiomyopathy: practical implications for heart failure management.

Authors:  Andrew N Rosenbaum; Katherine E Agre; Naveen L Pereira
Journal:  Nat Rev Cardiol       Date:  2019-10-11       Impact factor: 32.419

6.  Role of angiotensin II type I (AT1 A1166C) receptor polymorphism in susceptibility of left ventricular dysfunction.

Authors:  Avshesh Mishra; Anshika Srivastava; Surendra Kumar; Tulika Mittal; Naveen Garg; Surendra Kumar Agarwal; Shantanu Pande; Balraj Mittal
Journal:  Indian Heart J       Date:  2015-05-07

Review 7.  The role and regulation of cardiac angiotensin-converting enzyme for noninvasive molecular imaging in heart failure.

Authors:  Omer Aras; Steven A Messina; Jamshid Shirani; William C Eckelman; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2007-04       Impact factor: 2.931

Review 8.  The renin angiotensin system as a risk factor for coronary artery disease.

Authors:  J A Farmer; G Torre-Amione
Journal:  Curr Atheroscler Rep       Date:  2001-03       Impact factor: 5.113

Review 9.  Genetic prediction of heart failure incidence, prognosis and beta-blocker response.

Authors:  Fabiana Filigheddu
Journal:  Mol Diagn Ther       Date:  2013-08       Impact factor: 4.074

Review 10.  Determined to Fail--the Role of Genetic Mechanisms in Heart Failure.

Authors:  Elham Kayvanpour; Hugo A Katus; Benjamin Meder
Journal:  Curr Heart Fail Rep       Date:  2015-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.